AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JUL 2 - (NewsRx.com & NewsRx.net) -- A Harvard School of Public Health researcher will be conducting a study to evaluate the efficacy of a recombinant canarypox HIV-1 vaccine in IV drug users.
S. Dhalla announced the clinical trial at the 36th Annual Society of Epidemiological Research (SER) Meeting held in Atlanta, Georgia, June 11-14, 2003.
"The efficacy of a recombinant canarypox ALVAC-vCP205 HIV-1 vaccine will be studied in an initially seronegative group of IV drug users, a disadvantaged community of individuals. Excluded will be those with mental illness, history of malignancy or immunodeficiency, pregnancy, active tuberculosis, and recent receipt of blood products or a vaccine," Dhalla said.
Over a period of three years, study subjects' risk-taking behaviors, immunogenicity (humoral and cell-mediated), and short-term adverse effects (related/unrelated to vaccination) will be assessed.
"Clinical equipoise is crucial in a randomized preventive trial, and strict ethical principles will be followed," Dhalla said.
The vaccine or placebo (0.5 ml of either) "will be administered as an IM injection into the left arm at 0, 1, 3, and 6 ...